Integrative -omics and HLA-ligandomics analysis to identify novel drug targets for ccRCC immunotherapy
Anna Reustle(University of Tübingen), Elke Schaeffeler(Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology)
Cited by 102
Related Papers
A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study
|The Lancet|2023|508